Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuroscience company Cortex Pharmaceuticals has received FDA permission to begin pilot phase II trials of CX717, a potential treatment for cognitive dysfunction arising from neuropsychiatric conditions such as Alzheimer's disease, ADHD and sleep disorders. The news has sent Cortex shares up by over 5%.
Subscribe to our email newsletter
The first study of CX717 in the US will be a double-blind, placebo-controlled study using positron emission tomography (PET) imaging to determine the response of patients with Alzheimer’s disease, as well as healthy elderly volunteers, to CX717.
In a similar study paradigm in primates, CX717 demonstrated specific activity in the prefrontal cortex, hippocampus and visual cortex, which are the key brain regions needed to improve memory, cognition and attention.
The study in Alzheimer’s disease will be followed shortly thereafter with a trial in ADHD.
These studies, as well as a sleep deprivation study currently underway in the UK, are key programs to ascertain the efficacy of CX717 and to validate the primate model used to identify potential drug candidates.